Published 30day notice

63436

Federal Register / Vol. 89, No. 150 / Monday, August 5, 2024 / Notices

lotter on DSK11XQN23PROD with NOTICES1

The Commissioner or designee shall
have the authority to select members of
other scientific and technical FDA
advisory committees (normally not to
exceed 10 members) to serve
temporarily as voting members and to
designate consultants to serve
temporarily as voting members when:
(1) expertise is required that is not
available among current voting standing
members of the Committee (when
additional voting members are added to
the Committee to provide needed
expertise, a quorum will be based on the
combined total of regular and added
members), or (2) to comprise a quorum
when, because of unforeseen
circumstances, a quorum is or will be
lacking. Because of the size of the
Committee and the variety in the types
of issues that it will consider, FDA may,
in connection with a particular
committee meeting, specify a quorum
that is less than a majority of the current
voting members. The Agency’s
regulations (21 CFR 14.22(d)) authorize
a committee charter to specify quorum
requirements.
If functioning as a medical device
panel, an additional non-voting
representative member of consumer
interests and an additional non-voting
representative member of industry
interests will be included in addition to
the voting members.
Further information regarding the
most recent charter and other
information can be found at https://
www.fda.gov/advisory-committees/
human-drug-advisory-committees/drugsafety-and-risk-management-advisorycommittee or by contacting the
Designated Federal Officer (see FOR
FURTHER INFORMATION CONTACT). In light
of the fact that no change has been made
to the committee name or description of
duties, no amendment will be made to
21 CFR 14.100.
This notice is issued under the
Federal Advisory Committee Act (5
U.S.C. 1001 et seq.). For general
information related to FDA advisory
committees, please visit us at http://
www.fda.gov/AdvisoryCommittees/
default.htm.
Dated: July 31, 2024.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2024–17243 Filed 8–2–24; 8:45 am]
BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Notice of Interest Rate on Overdue
Debts
Section 30.18 of the Department of
Health and Human Services’ claims
collection regulations (45 CFR part 30)
provides that the Secretary shall charge
an annual rate of interest, which is
determined and fixed by the Secretary
of the Treasury after considering private
consumer rates of interest on the date
that the Department of Health and
Human Services becomes entitled to
recovery. The rate cannot be lower than
the Department of Treasury’s current
value of funds rate or the applicable rate
determined from the ‘‘Schedule of
Certified Interest Rates with Range of
Maturities’’ unless the Secretary waives
interest in whole or part, or a different
rate is prescribed by statute, contract, or
repayment agreement. The Secretary of
the Treasury may revise this rate
quarterly. The Department of Health and
Human Services publishes this rate in
the Federal Register.
The current rate of 117⁄8%, as fixed by
the Secretary of the Treasury, is certified
for the quarter ended June 30, 2024.
This rate is based on the Interest Rates
for Specific Legislation, ‘‘National
Health Services Corps Scholarship
Program (42 U.S.C. 254o(b)(1)(A))’’ and
‘‘National Research Service Award
Program (42 U.S.C. 288(c)(4)(B)).’’ This
interest rate will be applied to overdue
debt until the Department of Health and
Human Services publishes a revision.
David C. Horn,
Director, Office of Financial Policy and
Reporting.
[FR Doc. 2024–17139 Filed 8–2–24; 8:45 am]
BILLING CODE 4150–04–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Submission for OMB Review; 30-Day
Comment Request; The Impact of
Clinical Research Training and Medical
Education at the Clinical Center on
Physician Careers in Academia and
Clinical Research
AGENCY:

National Institutes of Health,

HHS.
ACTION:

Notice.

In compliance with the
Paperwork Reduction Act of 1995, the
National Institutes of Health (NIH) has
submitted to the Office of Management

SUMMARY:

VerDate Sep<11>2014

18:38 Aug 02, 2024

Jkt 262001

PO 00000

Frm 00039

Fmt 4703

Sfmt 4703

and Budget (OMB) a request for review
and approval of the information
collection listed below.
DATES: Comments regarding this
information collection are best assured
of having their full effect if received
within 30 days of the date of this
publication.
ADDRESSES: Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the data collection plans and
instruments, contact: Tom Burklow,
MD, Office of Clinical Research Training
and Medical Education, NIH Clinical
Center, National Institutes of Health, 10
Center Drive, Room 1N262, Bethesda,
MD 20892–1158, or call non-toll-free
number 301–435–8015, or Email your
request, including your address to:
tom.burklow@nih.gov.
SUPPLEMENTARY INFORMATION: This
proposed information collection was
previously published in the Federal
Register on May 13, 2024 (89 FR 41446)
and allowed 60 days for public
comment. No comments were received.
The purpose of this notice is to allow an
additional 30 days for public comment.
The Clinical Center, National Institutes
of Health, may not conduct or sponsor,
and the respondent is not required to
respond to, an information collection
that has been extended, revised, or
implemented on or after October 1,
1995, unless it displays a currently valid
OMB control number.
In compliance with section
3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National
Institutes of Health (NIH) has submitted
to the Office of Management and Budget
(OMB) a request for review and
approval of the information collection
listed below.
Proposed Collection: The Impact of
Clinical Research Training and Medical
Education at the Clinical Center on
Physician Careers in Academia and
Clinical Research, OMB #0925–0602
Expiration Date: 6/30/2024, National
Institutes of Health Clinical Center (CC),
National Institutes of Health (NIH).
Need and Use of Information
Collection: The information collected
will allow continued assessment of the
value of the training provided by the
Office of Clinical Research Training and

E:\FR\FM\05AUN1.SGM

05AUN1

63437

Federal Register / Vol. 89, No. 150 / Monday, August 5, 2024 / Notices
Medical Education (OCRTME) at the
NIH Clinical Center and the extent to
which this training promotes (a) patient
safety; (b) research productivity and
independence; and (c) future career
development within clinical,
translational, and academic research
settings. The information received from
respondents is presented to, evaluated

clinical research training and medical
education of the highest quality to each
trainee.
OMB approval is requested for 3
years. There are no costs to respondents
other than their time. The total
estimated annualized burden hours 537.

by, and incorporated into the ongoing
operational improvement efforts of the
Director of the Office of Clinical
Research Training and Education, and
the Chief Executive Officer of the NIH
Clinical Center. This information will
enable the ongoing operational
improvement efforts of the OCRTME
and its commitment to providing

ESTIMATED ANNUALIZED BURDEN HOURS
Number of
responses per
respondent

Average
burden per
response
(in hours)

Total annual
burden hours

Type of respondents

Clinical Research Training Program/Medical Research Scholars Program Alumni Survey.
Graduate Medical Education Graduate Survey ....
Clinical Electives Program 1 Year Alumni Survey
Continuing Medical Education Evaluation Survey

Physicians ....................

800

1

20/60

267

Physicians ....................
Physicians ....................
Physicians ....................

350
100
720

1
1
1

20/60
20/60
10/60

117
33
120

Total ...............................................................

.......................................

1,970

1,970

........................

537

Frederick D. Vorck, Jr.,
Project Clearance Liaison, NIH Clinical
Center, National Institutes of Health.
[FR Doc. 2024–17191 Filed 8–2–24; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Statement of Organization, Functions,
and Delegations of Authority
Substance Abuse and Mental
Health Services Administration
(SAMHSA).
ACTION: Organization, functions, and
delegations of authority.
AGENCY:

SAMHSA has modified its
organizational structure.
SUPPLEMENTARY INFORMATION: Part M of
the Substance Abuse and Mental Health
Services Administration (SAMHSA)
Statement of Organization, Functions,
and Delegations of Authority for the
Department of Health and Human
Services at 71 FR 19740–19741, April
17, 2006, is amended to reflect changes
of the functional statements for the
Center for Substance Abuse Treatment
(CSAT). This amendment reflects the
addition of one new division and two
branches. CSAT has taken the lead in
addressing the substance use disorder
(SUD) treatment needs of Americans,
focusing primarily on opioid treatment,
developing a crisis continuum,
improving adult and adolescent
substance use treatment, and increasing
access to and the quality of SUD
treatment and recovery services. CSAT
SUMMARY:

lotter on DSK11XQN23PROD with NOTICES1

Number of
respondents

Form name

VerDate Sep<11>2014

18:38 Aug 02, 2024

Jkt 262001

is dedicated to collaborating with
grantees and stakeholders to enhance
the accessibility of innovative services
and evidence-based treatment
modalities through grants and technical
assistance.
In order to enhance administrative
and operational efficiencies, CSAT
proposes that each supervisor within
the center should have a staff to
supervisor ratio of 1 supervisor to 10
staff person or less. There is currently a
twelve to one staff to supervisor ratio in
the Division of Services Improvement
(DSI)—with one branch having 17 staff.
Managing 10 or more employees can be
challenging for a first-line supervisor,
who must effectively handle employee
management and oversee grants and
contracts. By adding the Division of
Health Systems Improvement (DHSI)
and two branches, Integrated Care
Branch (ICB) and Opioid Treatment
Branch (OTB) the staff to supervisor
ratio would decrease to eight to one.
Moreover, streamlined and smaller
divisions/branches, with specific focus
areas, will provide additional oversight
and management by the second-level
supervisor for these important Federal
grants and contracts.
Center for Substance Abuse Treatment
Division of Health Systems
Improvement
The proposed DHSI will focus on
equity, medications for opioid use
disorder (MOUD), and the continuum of
care consistent with and necessary for
the achievement of goals outlined in the
President’s Unity Agenda and the Office
of National Drug Control Policy’s
National Drug Control Strategy. Refining
the alignment of grant portfolios by the

PO 00000

Frm 00040

Fmt 4703

Sfmt 4703

scope and span of grants and function,
subject matter areas, age group focus
(adolescents versus adults), and
geographic focus (community versus
state) will allow for improved
efficiencies and service. The two
branches in DHSI will be ICB and OTB.
The new division will allow for
dedicated leadership focusing on opioid
treatment, developing a crisis
continuum, improving adult and
adolescent substance use treatment, and
increasing access to and the quality of
SUD treatment and recovery services.
The proposed new division and two
new branches are better aligned based
on content and goal; the major grant
programs impacted by this change are
described below.
ICB will primairly focus on increasing
access to and improving the quality of
services of comprehensive, coordinated,
patient-centered care across the
continuum. The branch will manage the
Minority AIDS Initiative (MAI) and
Screening, Brief Intervention, and
Referral to Treatment (SBIRT) programs
both of which are authorized under the
Public Health Service Act (PHSA), title
V, section 509. MAI seeks to increase
engagement in care for racial and ethnic
underrepresented individuals with SUD
and/or co-occurring substance use and
mental disorders (COD) who are at risk
for or living with HIV/AIDS and receive
HIV/AIDS services/treatment. SBIRT is
a comprehensive, integrated, public
health approach to the delivery of early
intervention and treatment services for
persons with substance use disorders, as
well as those who are at risk of
developing these disorders.
• OTB will primarily focus on
providing evidence-based

E:\FR\FM\05AUN1.SGM

05AUN1